This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mark's Most Recent Article

The Run-Up Trade: Biodel's Insulin Trial Results

05/30/13 - 08:00 AM EDT

Biodel shares should move higher ahead of insulin trial results in the third quarter.

read more >

Other Articles by Mark

Free Reports

Rockwell Medical Run-Up Trade Follows Financing

05/21/13 - 08:00 AM EDT

One trader believes Rockwell shares will rise into clinical trial results expected in July.

read more >
Synta Is Run-Up to ASCO Lung Cancer Data

05/14/13 - 10:16 AM EDT

The market overreacted to the resignation of Synta's R&D chief.

read more >
Expecting Ziopharm Shares To Run Into Phase III Data At Month's End

03/04/13 - 07:00 AM EST

Ziopharm is an example of a stock with clinical trial results that can be traded realtively safely.

read more >
Run-Up Trade Into Dynavax's FDA Approval Decision

02/13/13 - 07:00 AM EST

Three factors that will cause Dynavax shares to gain as get closer to the approval of its Hep B vaccine.

read more >
Titan Pharma: Run-Up Trade Into March FDA Panel

01/31/13 - 06:03 AM EST

I expect traders will get an opportunity to profit from increased focus on Titan through March.

read more >
A.P. Pharma Run-Up Trade Into FDA Approval Decision

01/22/13 - 08:32 AM EST

Look at A.P. Pharma as a trade, not as a long-term investment, says trader Mark Messier.

read more >
Shorting Alexza Pharma On FDA's Adasuve Approval

12/19/12 - 07:00 AM EST

Alexza is setting up as a classic biotech run-down stock, says trader Mark Messier.

read more >
Anacor Pharma: Run-Up Trade Into January Trial Data

12/11/12 - 08:29 AM EST

Anacor will be releasing phase III results for a toenail fungus drug in January.

read more >
Hyperion Shares Poised to Run Up Ahead of FDA Decision

12/05/12 - 08:00 AM EST

FDA expected to issue approval decision on orphan drug Ravicti on Jan. 23.

read more >
Page 1 of 2
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs